anakinra
information and resources from the National Cancer Institute
NCI Thesaurus | anakinra
A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist with potential antineoplastic activity. Anakinra binds to the IL-1 receptor, thereby blocking the binding of the IL-1 to and activation of its receptor. Blockade of IL-1 activity may inhibit the cascade of downstream pro-angiogenic factors such as vascular endothelial cell growth factor, tumor necrosis factor-alpha, and IL-6, resulting in inhibition of tumor angiogenesis. NCI Thesaurus | anakinra
A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist with potential antineoplastic activity. Anakinra binds to the IL-1 receptor, thereby blocking the binding of the IL-1 to and activation of its receptor. Blockade of IL-1 activity may inhibit the cascade of downstream pro-angiogenic factors such as vascular endothelial cell growth factor, tumor necrosis factor-alpha, and IL-6, resulting in inhibition of tumor angiogenesis.
|
|
|
|
news articles
Juvenile Arthritis - A Niche In The Market 21 Dec 2005
Pharmaceutical Business Review Kineret (anakinra) the only IL-1 inhibitor currently available, does not appear to be in development for JIA, but Actemra (tocilizumab) is expected to launch ...
Juvenile Arthritis - A Niche In The Market 21 Dec 2005
Pharmaceutical Business Review Kineret (anakinra) the only IL-1 inhibitor currently available, does not appear to be in development for JIA, but Actemra (tocilizumab) is expected to launch ...
|
|
